What is CareDx?
Founded in 1998 and headquartered in South San Francisco, CareDx operates at the intersection of biotechnology and digital health. The company specializes in the discovery, development, and commercialization of clinically differentiated solutions tailored for transplant patients and their caregivers. By providing comprehensive testing services and genomics-based insights, CareDx effectively manages the complex pre- and post-transplant patient journey. Its market position is defined by a commitment to improving long-term patient outcomes through high-precision diagnostic tools and integrated digital healthcare platforms, making it a pivotal player in the transplant medicine ecosystem.
How much funding has CareDx raised?
CareDx has raised a total of $98.5M across 5 funding rounds:
Debt
$6M
Debt
$12.5M
Debt
$15M
Stock Offering
$40M
Debt
$25M
Debt (2010): $6M, investors not publicly disclosed
Debt (2011): $12.5M led by GE Capital Healthcare Financial Services
Debt (2012): $15M supported by Oxford Finance Corporation and Silicon Valley Bank
Stock Issuance/Offering (2014): $40M, investors not publicly disclosed
Debt (2017): $25M, investors not publicly disclosed
Key Investors in CareDx
Oxford Finance Corporation
A specialty finance firm providing flexible capital solutions tailored specifically for the unique needs of healthcare and life sciences enterprises.
Silicon Valley Bank
A prominent financial institution offering specialized banking, asset management, and investment services to the innovation and technology sectors.
GE Capital Healthcare Financial Services
A financial services entity focused on providing investment advisory and capital support to companies operating within the healthcare industry.
What's next for CareDx?
Looking ahead, CareDx is positioned to leverage its recent capital injection to scale its digital healthcare infrastructure and expand its genomics-based product portfolio. The strategic focus remains on enhancing the accessibility of its transplant diagnostic services while integrating advanced data analytics to support clinical decision-making. As the company matures, the emphasis will likely shift toward broader market penetration and the development of next-generation diagnostic markers. By maintaining a rigorous focus on clinical differentiation, CareDx is well-equipped to address the evolving needs of the transplant medicine market, ensuring sustained value creation for stakeholders and improved quality of life for patients globally.
See full CareDx company page
